

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



和 鉑 醫 藥 控 股 有 限 公 司

**HBM Holdings Limited**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 02142)**

## **VOLUNTARY ANNOUNCEMENT**

### **ENTERING INTO LICENSE AGREEMENT WITH VISTERRA, INC.**

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Nona Biosciences US, Inc. (“**Nona Biosciences**”), a wholly owned subsidiary of the Company, has entered into a license agreement with Visterra, Inc. (“**Visterra**”) to advance Visterra’s next-generation biotherapeutic pipeline for immune-mediated and autoimmune diseases, leveraging Nona Biosciences’ proprietary heavy-chain-only antibody (“**HCAb**”) Harbour Mice® technology platform.

Nona Biosciences’ HCAb Harbour Mice® platform enables the generation of fully human HCABs, offering key advantages such as reduced immunogenicity and enhanced versatility for next-generation biotherapeutics. This innovative platform has been clinically validated and widely recognized by global partners.

#### **About Nona Biosciences**

Nona Biosciences, a wholly owned subsidiary of the Company, is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from “Idea to IND” (“**I to I™**”), ranging from target validation and antibody discovery through preclinical research. Its integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (“**H2L2**”) format, and HCAb format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs.

## About Visterra

Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases. For further information, please refer to the website of Visterra at [www.visterrainc.com](http://www.visterrainc.com).

**Cautionary Statement:** There is no assurance that any products as stated in this announcement will ultimately be successfully developed and marketed by the Company or the collaboration partner. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**HBM Holdings Limited**  
**Dr. Jingsong Wang**  
*Chairman and Executive Director*

Hong Kong, 12 June 2025

*As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.*